Simplifying
Cervical Cancer prevention with Mia
Prevention, redefined for you
Download 
Comfortable Experience
Our gentle, speculum-free swab is performed in your physician’s office—quick, easy, and pain-free for patients
Comprehensive Testing
Mia detects high-risk HPV DNA and oncogene activity via E6/E7 mRNA in one simple step—no repeat collections needed
Empower Your Patients
Accurate results and a patient-friendly approach build trust and promote better health outcomes
Cervical cancer is highly preventable — yet it still claims hundreds of thousands of lives worldwide every year
4th
Leading cause
of cancer/cancer deaths (WHO 2022)
660K
New cases
detected each year (WHO 2022)
350K
Women die
from cervical cancer each year (WHO 2022)
Mia Comprehensive Cervical Cancer Test identifies:
- 14 high-risk HPV DNA genotypes with confidence.
- Confirms active infections by detecting E6/E7 mRNA expression for seven HPV types.
Guiding Clinicians with Clarity, Confidence, and Compassion!
Why Mia is Good for Patients — and Good for Your Practice
Our Mia Comprehensive Cervical Cancer Test transforms what cervical cancer looks like—bringing comfort, clarity, and confidence to both patients and clinicians.
Serve more women,
more consistently
HPV affects more than two-thirds of young women within two years of becoming sexually active. Mia is suitable for all sexually active women between 25 and 64 or have ever had an abnormal Pap or HPV result, giving your practice a large, sustainable population to serve.
Practice impact
- Expands your eligible screening population and supports ongoing patient flow.
Better Clinical Insight,
Fewer Repeat Visits
Mia’s dual testing for Hr-HPV DNA 14 genotypes and E6/E7 mRNA seven genotypes oncogene activity automatically differentiates between transient infections and those likely to progress to cancer, giving providers a clearer picture of cervical cancer risk.
Practice impact
- Enables early intervention
- Reduces unnecessary colposcopies and biopsies
- Improve patient experience
From detection
to decisions
Mia’s reporting distinguishes between high-risk HPV DNA and active E6/E7 HPV mRNA oncogene overexpression. This improves cervical cancer screening accuracy and makes follow-up decisions easier.
Practice Impact:
- Supports efficient, evidence-based patient management and strengthens your practice’s
Easier to offer.
Easier to schedule.
Easier to say yes.
Serve more women,
more consistently
HPV affects more than two-thirds of young women within two years of becoming sexually active. Mia is suitable for all sexually active women between 25 and 64 or have ever had an abnormal Pap or HPV result, giving your practice a large, sustainable population to serve.
Practice impact
- Expands your eligible screening population and supports ongoing patient flow.
Better Clinical Insight,
Fewer Repeat Visits
Mia’s dual testing for Hr-HPV DNA 14 genotypes and E6/E7 mRNA seven genotypes oncogene activity automatically differentiates between transient infections and those likely to progress to cancer, giving providers a clearer picture of cervical cancer risk.
Practice impact
- Enables early intervention
- Reduces unnecessary colposcopies and biopsies
- Improve patient experience
From detection
to decisions
Mia’s reporting distinguishes between high-risk HPV DNA and active E6/E7 HPV mRNA oncogene overexpression. This improves cervical cancer screening accuracy and makes follow-up decisions easier.
Practice Impact:
- Supports efficient, evidence-based patient management and strengthens your practice’s
Easier to offer.
Easier to schedule.
Easier to say yes.
In-office HPV risk stratification test designed to be painless and speculum-free
It can be used during light menstruation, simplifying appointment scheduling
Show your practice follows
best-in-class preventive
care standards
Mia supports extended screening intervals (every 3–5 years if negative result)
Bring Mia to your Women’s Health Program
Offer a gentler, smarter, guideline-aligned cervical cancer screening experience
Talk to Us
How to Integrate Mia into Your Practice
Our Mia Comprhensive Cervical Cancer Test transforms what cervical cancer looks like—bringing comfort, clarity, and confidence to both patients and clinicians.
Collect Sample
Collect vaginal specimens without using a speculum during your routine visit
Submit Sample
Ship to the lab using provided kit and return label
Receive Report
Get a comprehensive report HPV DNA & E6/E7 mRNA
Providers can trust Mia to deliver reliable results that support patient safety and efficient care
Reliable Cervical Cancer Risk Stratification
Backed by global studies, Mia demonstrates higher specificity and predictive accuracy, fewer unnecessary procedures, and strong long-term outcomes.
127,000+
Validated cases in women worldwide
2x
Higher predictive accuracy
50%
Fewer unnecessary Colposcopies/biopsies